Ebos Group (ASX:EBO) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EBO Ebos Group Ltd ASX:EBO
77 GF Score
Price A$15.70
GF Value A$30.81
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Ebos Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ebos Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$151 Mil. Ebos Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$1,744 Mil. Ebos Group's annualized EBITDA for the quarter that ended in Jun. 2026 was A$587 Mil. Ebos Group's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 3.23.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ebos Group's Debt-to-EBITDA or its related term are showing as below:

ASX:EBO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.91   Med: 2.5   Max: 4.12
Current: 3.29

During the past 13 years, the highest Debt-to-EBITDA Ratio of Ebos Group was 4.12. The lowest was 1.91. And the median was 2.50.

ASX:EBO's Debt-to-EBITDA is ranked worse than
63.44% of 93 companies
in the Medical Distribution industry
Industry Median: 2.29 vs ASX:EBO: 3.29

Ebos Group  (ASX:EBO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Ebos Group Debt-to-EBITDA Related Terms

Ebos Group Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Ebos Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group Debt-to-EBITDA Chart

Ebos Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ebos Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ASX:EBO vs MCK, COR, CAH: Debt-to-EBITDA Comparison

For the Medical Distribution subindustry, Ebos Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group Debt-to-EBITDA vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ebos Group's Debt-to-EBITDA falls into.


ASX:EBO
77GF Score
Ebos Group Ltd ASX:EBO
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ebos Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ebos Group's Debt-to-EBITDA for the fiscal year that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(151.26000000032 + 1744.4790000037) / 591.7500000008
=3.20

Ebos Group's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(151.26000000032 + 1744.4790000037) / 586.83200000148
=3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Is Ebos Group (ASX:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of A$15.70 is trading 49% below its estimated GF Value™ of A$30.81. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for ASX:EBO:

  • Debt-to-EBITDA:
  • GF Value™: A$30.81 vs. price of A$15.70 (49% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score

Get the complete analysis for ASX:EBO

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$15.70
Price
A$30.81
GF Value